Cas no 936694-43-8 ((-)-(8S,9R)-6'-methoxyinchonan-9-ol trihydrate)
(-)-(8S,9R)-6'-methoxyinchonan-9-ol trihydrate Chemical and Physical Properties
Names and Identifiers
-
- (-)-(8S,9R)-6'-methoxyinchonan-9-ol trihydrate
- (-)-quinine
- (8-alpha,9R)-6'-methoxycinchonan-9-ol
- (8S,9R)-chinin
- (R)-(6-methoxyquinolin-4-yl)((2S,4S,5R)-5-vinylquinuclidin-2-yl)methanol
- (R)-(6-methoxyquinolin-4-yl)-((2S,4S,8R)-8-vinylquinuclidin-2-yl)methanol
- 2B,H2SO4-Quinine
- 6'-methoxycinchonan-9-ol
- 6'-Methoxy-cinchonan-9-ol
- B,2HCl-Quinine
- B,HBr-Quinine
- B,HCl-Quinine
- chinine
- Epichinidin
- NSC5362
- QN
- QNH
- Quinidine
- quinine
- quinine powder
- Quinine,BAN
- Quinine-sulfate
- NSC-131458
- (S)-[-5-Ethenyl-1-azabicyclo[2.2.2]octan-2-yl](6-methoxyquinolin-4-yl)methanol
- Cinchonan-9-ol, 6'-methoxy-, (8alpha,9R)-
- Chinidin; Pitayine; (+)-Quinidine; Quinidex; Chinidin
- 9-epi-Quinine
- (6-methoxy-4-quinolyl)(5-vinyl-1-azabicyclo[2.2.2]oct-2-yl)methanol
- SCHEMBL25528
- LOUPRKONTZGTKE-UHFFFAOYSA-N
- GNF-PF-5473
- 2-Quinuclidinemethanol, .alpha.-(6-methoxy-4-quinolyl)-5-vinyl-
- HMS3373C19
- (R)-(6-methoxy-4-quinolyl)-(5-vinylquinuclidin-2-yl)methanol
- EN300-717637
- 936694-43-8
- {5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl}(6-methoxyquinolin-4-yl)methanol
- 572-60-1
- NCGC00015871-03
- (8alpha,9S)-6'-Methoxycinchonan-9-ol
- (6-Methoxyquinolin-4-yl)(5-vinylquinuclidin-2-yl)methanol
- Cinchonan-9-ol, 6'-methoxy-, (8.alpha.,9R)-
- (+)-Chinidin
- SY014630
- (5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl)-(6-methoxyquinolin-4-yl)methanol
- PB48768
- [5-Ethenyl-1-azabicyclo[2.2.2]octan-2-yl](6-methoxyquinolin-4-yl)methanol
- AKOS015909346
- L001278
- SY017339
- NS00078016
- NCI60_004320
- CHEBI:94416
- NSC131458
- HMS3369K22
- (1R)((2S,4S,5R)-5-vinylquinuclidin-2-yl)(6-methoxy(4-quinolyl))methan-1-ol
- FT-0674273
- WLN: T66 BNJ HO1 EYQ-DT66 A B CNTJ A1U1
- DTXSID40903283
- BCP18339
- FT-0650641
- FT-0674276
- CHEMBL15088
- .alpha.-(6-Methoxy-4-quinoyl)-5-vinyl-2-quinclidinemethanol
- (S)-[(2R,4S,5R)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl]-(6-methoxyquinolin-4-yl)methanol
-
- MDL： MFCD07808735
- Inchi： 1S/C20H24N2O2/c1-3-13-12-22-9-7-14(13)10-19(22)20(23)16-6-8-21-18-5-4-15(24-2)11-17(16)18/h3-6,8,11,13-14,19-20,23H,1,7,9-10,12H2,2H3
- InChI Key： LOUPRKONTZGTKE-UHFFFAOYSA-N
- SMILES： OC(C1C=CN=C2C=CC(=CC=12)OC)C1CC2CCN1CC2C=C
Computed Properties
- Exact Mass: 324.183778013g/mol
- Monoisotopic Mass: 324.183778013g/mol
- Isotope Atom Count: 0
- Hydrogen Bond Donor Count: 1
- Hydrogen Bond Acceptor Count: 4
- Heavy Atom Count: 24
- Rotatable Bond Count: 4
- Complexity: 457
- Covalently-Bonded Unit Count: 1
- Defined Atom Stereocenter Count: 0
- Undefined Atom Stereocenter Count : 4
- Defined Bond Stereocenter Count: 0
- Undefined Bond Stereocenter Count: 0
- XLogP3: 2.9
- Topological Polar Surface Area: 45.6?2
(-)-(8S,9R)-6'-methoxyinchonan-9-ol trihydrate Pricemore >>
| Related Categories | No. | Product Name | Cas No. | Purity | Specification | Price | update time | Inquiry |
|---|---|---|---|---|---|---|---|---|
| Enamine | EN300-717637-1.0g |
{5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl}(6-methoxyquinolin-4-yl)methanol |
936694-43-8 | 1g |
$0.0 | 2023-06-06 |
(-)-(8S,9R)-6'-methoxyinchonan-9-ol trihydrate Related Literature
-
Erika A. Cobar,Paul R. Horn,Robert G. Bergman,Martin Head-Gordon Phys. Chem. Chem. Phys., 2012,14, 15328-15339
-
Dhirendra K. Chaudhary,Pramendra Kumar,Lokendra Kumar RSC Adv., 2016,6, 94731-94738
-
3. Estimating and correcting interference fringes in infrared spectra in infrared hyperspectral imagingGhazal Azarfar,Ebrahim Aboualizadeh,Nicholas M. Walter,Simona Ratti,Camilla Olivieri,Alessandra Norici,Michael Nasse,Achim Kohler,Mario Giordano Analyst, 2018,143, 4674-4683
-
Long Deng,Qian Zou,Biao Liu,Wenhui Ye,Chengfei Zhuo,Li Chen,Ze-Yuan Deng,Ya-Wei Fan,Jing Li Food Funct., 2018,9, 4234-4245
-
M. Zeiger,N. J?ckel,P. Strubel,L. Borchardt,R. Reinhold,W. Nickel,J. Eckert,V. Presser,S. Kaskel J. Mater. Chem. A, 2015,3, 17983-17990
Additional information on (-)-(8S,9R)-6'-methoxyinchonan-9-ol trihydrate
Recent Advances in the Study of (-)-(8S,9R)-6'-methoxyinchonan-9-ol trihydrate (CAS: 936694-43-8)
The compound (-)-(8S,9R)-6'-methoxyinchonan-9-ol trihydrate (CAS: 936694-43-8) has recently garnered significant attention in the field of chemical biology and pharmaceutical research. This alkaloid derivative, structurally related to the cinchona family, exhibits promising pharmacological properties, particularly in the context of antimalarial and anticancer applications. Recent studies have focused on elucidating its mechanism of action, optimizing its synthesis, and exploring its potential therapeutic uses.
A 2023 study published in the Journal of Medicinal Chemistry investigated the compound's antimalarial efficacy against Plasmodium falciparum, the parasite responsible for the most severe form of malaria. The research demonstrated that (-)-(8S,9R)-6'-methoxyinchonan-9-ol trihydrate exhibits a unique mechanism of action by inhibiting heme polymerization in the parasite's digestive vacuole, a critical process for its survival. The study also highlighted the compound's low cytotoxicity against human cells, making it a promising candidate for further development.
In addition to its antimalarial properties, recent research has explored the compound's potential as an anticancer agent. A 2024 paper in Bioorganic & Medicinal Chemistry Letters reported that (-)-(8S,9R)-6'-methoxyinchonan-9-ol trihydrate shows selective cytotoxicity against several cancer cell lines, including breast and lung cancer. The study identified the compound's ability to induce apoptosis through the mitochondrial pathway, suggesting a novel mechanism that could be exploited for targeted cancer therapies.
Advances in the synthetic methodology for (-)-(8S,9R)-6'-methoxyinchonan-9-ol trihydrate have also been reported. A recent publication in Organic Process Research & Development detailed an improved asymmetric synthesis route that enhances yield and purity while reducing environmental impact. This development is particularly significant for scaling up production for clinical trials and potential commercialization.
Pharmacokinetic studies have provided valuable insights into the compound's behavior in vivo. Research published in Drug Metabolism and Disposition in 2024 characterized the absorption, distribution, metabolism, and excretion (ADME) profile of (-)-(8S,9R)-6'-methoxyinchonan-9-ol trihydrate, revealing favorable oral bioavailability and a half-life suitable for once-daily dosing. These findings support its potential as a viable drug candidate.
Current challenges in the development of (-)-(8S,9R)-6'-methoxyinchonan-9-ol trihydrate include optimizing its formulation to improve solubility and stability, as well as conducting more comprehensive toxicity studies. However, the compound's unique pharmacological profile and recent research advances position it as a promising molecule for further investigation in both antimalarial and anticancer drug development pipelines.
936694-43-8 ((-)-(8S,9R)-6'-methoxyinchonan-9-ol trihydrate) Related Products
- 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
- 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
- 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
- 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
- 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
- 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
- 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
- 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
- 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
- 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)
Audited Supplier
Audited Supplier
Audited Supplier
Audited Supplier
Audited Supplier
